头孢哌酮联合舒巴坦治疗慢性心力衰竭患者肺部感染的临床分析

发布时间：2019-03-06 17:39

【摘要】：目的探讨头孢哌酮联合舒巴坦治疗慢性心力衰竭患者肺部感染的临床疗效及安全性,为临床用药提供参考。方法选取2014年1-12月在医院治疗的慢性心力衰竭合并肺部感染患者180例,采取随机将其分为对照组和观察组,各90例,对照组患者给予头孢哌酮治疗,观察组患者采用头孢哌酮联合舒巴坦治疗,对两组患者的临床疗效进行分析比较。结果对照组在临床体征方面明显不如观察组,差异有统计学意义(P0.05);经过治疗后,治疗有效率对照组为70.00%;观察组为94.44%,差异有统计学意义(P0.05);观察组经过头孢哌酮联合舒巴坦治疗后,其在平喘、咳嗽消失时间、肺部湿Up音被吸收时间及退热时间等指标明显低于对照组,差异有统计学意义(P0.01)。结论头孢哌酮联合舒巴坦治疗慢性心力衰竭合并肺部感染临床效果显著,临床用药安全性高,能快速改善患者临床症状,缓解患者痛苦,临床应用价值值得推广。
[Abstract]:Objective to investigate the clinical efficacy and safety of cefoperazone combined with sulbactam in the treatment of pulmonary infection in patients with chronic heart failure. Methods 180 patients with chronic heart failure complicated with pulmonary infection treated in hospital from January to December 2014 were randomly divided into control group (n = 90) and observation group (n = 90). The patients in control group were treated with cefoperazone. The patients in the observation group were treated with cefoperazone combined with sulbactam, and the clinical effects of the two groups were analyzed and compared. Results the clinical signs of the control group were significantly lower than that of the observation group (P0.05); after treatment, the effective rate of the control group was 70.00%; the observation group was 94.44%, the difference was statistically significant (P0.05). After treatment with cefoperazone and sulbactam, the indexes of asthma, cough disappearance time, lung wet Up sound absorption time and fever relieving time in the observation group were significantly lower than those in the control group (P0.01). Conclusion Cefoperazone combined with sulbactam is effective and safe in the treatment of chronic heart failure with pulmonary infection. It can rapidly improve the clinical symptoms and relieve the pain of the patients. The clinical value of cefoperazone and sulbactam is worth popularizing.
【作者单位】：郑州市中医院心内科;
【基金】：河南卫生厅重点基金资助项目(XL20140507)
【分类号】：R563.1;R541.6

【相似文献】